Evogene Ltd. (EVGN)

IL — Healthcare Sector
Peers: RCUS  FATE  SURF  PLUR  LEXX  NAVB  ZVSA  BDRX  ONCR  CANF  ICCC  CGEN  CLGN    PLX  CRVS  ALDX  GMDA  CKPT 

Automate Your Wheel Strategy on EVGN

With Tiblio's Option Bot, you can configure your own wheel strategy including EVGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol EVGN
  • Rev/Share 1.2524
  • Book/Share 2.1835
  • PB -5.1751
  • Debt/Equity -8.8725
  • CurrentRatio 1.1548
  • ROIC -0.7079

 

  • MktCap 7372751.0
  • FreeCF/Share -2.9911
  • PFCF -0.3627
  • PE -0.4555
  • Debt/Assets 0.3229
  • DivYield 0
  • ROE -11.8554

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Evogene Ltd. (EVGN) Q1 2025 Earnings Call Transcript
EVGN
Published: May 21, 2025 by: Seeking Alpha
Sentiment: Neutral

Evogene Ltd. (NASDAQ:EVGN ) Q1 2025 Earnings Conference Call May 21, 2025 9:00 AM ET Company Participants Ofer Haviv - President and Chief Executive Officer Yaron Eldad - Chief Financial Officer Operator Welcome to Evogene's First Quarter 2025 Results Conference Call.

Read More
image for news Evogene Ltd. (EVGN) Q1 2025 Earnings Call Transcript
Evogene Schedules First Quarter 2025 Financial Results Release
EVGN
Published: May 08, 2025 by: PRNewsWire
Sentiment: Neutral

Zoom conference call scheduled for May 21, 2025, 9:00 AM ET REHOVOT, Israel , May 8, 2025 /PRNewswire/ -- May 8, 2025 - Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the first quarter of 2025, on Wednesday, May 21, 2025.

Read More
image for news Evogene Schedules First Quarter 2025 Financial Results Release
ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio
EVGN
Published: April 21, 2025 by: PRNewsWire
Sentiment: Neutral

Lavie Bio improves agriculture productivity and sustainability through microbiome-based ag-biological products REHOVOT, Israel , April 21, 2025 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) a leading computational biology company focused on revolutionizing life-science-based product discovery and development, today announced the signing of a definitive agreement under which ICL, will acquire the majority of activity of Evogene's subsidiary, Lavie Bio Ltd.

Read More
image for news ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio
Evogene Ltd. (EVGN) Q4 2024 Earnings Call Transcript
EVGN
Published: March 06, 2025 by: Seeking Alpha
Sentiment: Neutral

Evogene Ltd. (NASDAQ:EVGN ) Q4 2024 Earnings Conference Call March 6, 2025 9:00 AM ET Company Participants Ofer Haviv - President and CEO Nir Nimrodi - Chairperson of the Board Yaron Eldad - Chief Financial Officer Operator Welcome to Evogene's Fourth Quarter Results Conference Call.

Read More
image for news Evogene Ltd. (EVGN) Q4 2024 Earnings Call Transcript
Evogene Schedules Fourth Quarter 2024 Financial Results Release
EVGN
Published: February 20, 2025 by: PRNewsWire
Sentiment: Neutral

Zoom conference call scheduled for March 6, 2025, 9:00 AM ET REHOVOT, Israel , Feb. 20, 2025 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the fourth quarter of 2024, on Thursday, March 6, 2025.

Read More
image for news Evogene Schedules Fourth Quarter 2024 Financial Results Release
AgPlenus Announces Discovery of a New Mode of Action for Fungicides Against Wheat Disease
EVGN
Published: February 13, 2025 by: PRNewsWire
Sentiment: Neutral

Initial fungicidally active compounds already discovered REHOVOT, Israel , Feb. 13, 2025 /PRNewswire/ -- AgPlenus Ltd., a global leader in designing and developing novel sustainable crop protection products and a subsidiary of Evogene Ltd.

Read More
image for news AgPlenus Announces Discovery of a New Mode of Action for Fungicides Against Wheat Disease

About Evogene Ltd. (EVGN)

  • IPO Date 2010-10-15
  • Website https://www.evogene.com
  • Industry Biotechnology
  • CEO Mr. Ofer Haviv CPA
  • Employees 117

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.